Clinical Advances for Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer (CRPC) is a major health problem that accounts for nearly 1 in 10 cancer-related deaths in men in the United States. Until very recently, limited treatment options were available that improved survival for these patients. This has now changed with the approval of a new immunotherapy for asymptomatic/minimally symptomatic patients and a new cytotoxic agent for patients previously treated with standard first-line therapy. Novel androgen-targeted agents and other agents or combinations targeting the tumor microenvironment are showing promise in late-stage clinical trials. However, bone metastases and the associated morbidity remain a major concern in these patients, with a receptor activator of nuclear factor-kappa B ligand (RANKL) inhibitor recently yielding a significant delay in the incidence of skeletal-related events compared with standard therapy.

This audio-based activity informs physicians of recent advances in the treatment of patients with metastatic CRPC.

Upon completion, participants should be able to:
• Assess current clinical data on emerging targeted therapies for patients with metastatic CRPC;
• Incorporate newly approved chemotherapy for appropriate patients with metastatic CRPC following docetaxel failure;
• Evaluate the safety and efficacy of RANKL-targeted therapy for patients with CRPC and bone metastases.

» Go to this activity

You are subscribed to ModernMedicine.com. To unsubscribe, click here

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.